Lupin launches generic PhosLo capsules in US market

Lupin has launched Calcium Acetate capsules, used in treating hyperphosphatemia in end stage renal failure, in the US after getting approval from United States Food and Drug Administration (USFDA).
Lupin Pharmaceuticals Inc, a subsidiary of the company, has launched Calcium Acetate capsules having received final approval from the American health regulator, the company said in a statement.
The Mumbai-based firm's product is the generic version of Fresenius Medical Care North America's PhosLo Gelcaps. The drug is indicated for the control of hyperphosphatemia in end stage renal failure.
As per IMS sales data, PhosLo Gelcaps had annual US sales of USD 54.5 million.

Shares of Lupin today ended at Rs 2,053.40 apiece on the BSE, down 1.25 per cent from previous close.